In two xenograft models of human HER2-positive ovarian cancer (SKOV-3) and esophageal cancer (OE19) we used PET imaging to evaluate tumor uptake of radiolabeled trastuzumab (SKOV-3 and OE19), IgG (in SKOV-3) and bevacizumab (SKOV-3), before and after bevacizumab treatment [60]. Here, ERBB2 is linked to neoplasm.